干擾素-α聯(lián)合拉米夫定治療慢性乙型肝炎臨床療效分析(2)
![]() |
| 第1頁(yè) |
參見(jiàn)附件(372KB,3頁(yè))。
responseuponadeno-associated virus (AAV) vector delivery into dendritic cells[J]. J Viral Hepat,2006,13(9):605.
[4]Daza P,Banda R,Misoya K,et al. The impact of routine infant im-munization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus preva-lence[J]. Vaccine,2006,24(37-39): 6232.
[5]Kwon CH,Suh KS,Yi NJ,et al. Long-term protection against hep-atitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation[J].Pediatr Transplant,2006, 10(4):479.
[6]何文生.干擾素的臨床應(yīng)用[J]. 現(xiàn)代醫(yī)藥衛(wèi)生,2006,22(10):1478.
[7]郇述玲,侯青順,王德欣,等. 乙型肝炎病毒基因型用干擾素α-2b聯(lián)合苦參素治療的臨床研究[J]. 現(xiàn)代醫(yī)藥衛(wèi)生,2006,22(24):3720.
[8]Martinot PM,Comanor L,Minor JM,et al. Accurate model predicting sustained response at week 4 of therapywithpegylatedinterferon with ribavirin in patients with chronic hepatitis C[J]. J Viral Hepat,2006,13(10):701.
[9]Itsui Y,Sakamoto N,Kurosaki M,et al. Expressional screening of in-terferon-stimulated genes for antiviralactivityagainsthepatitis C virus replication[J]. J Viral Hepat,2006,13(10): 690.
[10]Munoz H,Arroyo J,Torres EA,et al. Response to combination ther-apy of interferon alfa-2b plus ribavirin in Hispanics with chronic hepatitis C[J]. PR Health Sci J,2004,23(2S): 61.
[11]Zheng S,Chen Y,Liang T,et al. Prevention of hepatitis B recurrenceafter liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis[J]. Liver Transpl,2006,12(2):253.
收稿日期:2007-03-15
注:本文中所涉及到的圖表、注解、公式等內(nèi)容請(qǐng)以PDF格式閱讀原文。
[ 上 頁(yè) ]
您現(xiàn)在查看是摘要介紹頁(yè),詳見(jiàn)PDF附件(372KB,3頁(yè))。
